Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery

Description

This prospective study aims to evaluate the safety and effectiveness of AVELI for reducing cellulite and fibrotic tissue in patients undergoing High-Definition Liposculpture, exploring if AVELI improves the aesthetic outcomes, and reduced the clinically evident cellulite and/or fibrosis. The main questions this study seeks to answer are: * Does AVELI safely reduce cellulite and fibrotic tissue without causing serious adverse events? * How effective is AVELI in improving patient-reported outcomes and aesthetic appearance? Through this study, the study team aims to evaluate the safety and effectiveness of AVELI. The study procedures include: * Baseline data collection of sociodemographic variables. Data collection of surgical variables, adverse events, and satisfaction scores. * All patients will undergo the standardized High-Definition Liposculpture technique, with AVELI applied to all identified cellulite and/or fibrosis release. * Photographic and 3D imaging preoperatively and at follow-ups (1, 3, 6, and 9 months).

Conditions

Liposuction, Cellulite, Cellulite Reduction, Fibrosis; Skin

Talk to us

Study Overview

On this page

Study Details

Study overview

This prospective study aims to evaluate the safety and effectiveness of AVELI for reducing cellulite and fibrotic tissue in patients undergoing High-Definition Liposculpture, exploring if AVELI improves the aesthetic outcomes, and reduced the clinically evident cellulite and/or fibrosis. The main questions this study seeks to answer are: * Does AVELI safely reduce cellulite and fibrotic tissue without causing serious adverse events? * How effective is AVELI in improving patient-reported outcomes and aesthetic appearance? Through this study, the study team aims to evaluate the safety and effectiveness of AVELI. The study procedures include: * Baseline data collection of sociodemographic variables. Data collection of surgical variables, adverse events, and satisfaction scores. * All patients will undergo the standardized High-Definition Liposculpture technique, with AVELI applied to all identified cellulite and/or fibrosis release. * Photographic and 3D imaging preoperatively and at follow-ups (1, 3, 6, and 9 months).

Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery

Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery

Condition
Liposuction
Intervention / Treatment

-

Contacts and Locations

Miami

Miami Aesthetic, Miami, Florida, United States, 33131

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients undergoing HDL between 18 and 60 years old.
  • * Non-gender specific.
  • * American Association of Anesthesiologist Risk Assessment (ASA) ≤ 2.
  • * Body Mass Index (BMI) ≥20 and ≤ 32 kg/m2.
  • * Patients with any degree of clinically evident cellulite in any body area.
  • * Patients with prior liposuction procedures with any degree of fibrosis in any body area.
  • * Patients undergoing additional procedures such as, but not limited to: Rhinoplasty, Mammaplasty, Mastopexy, mini tummy tuck, full tummy tuck, brachioplasty, thighplasty, fat grafting. The procedure could not be related to the treatment of fibrosis or cellulite.
  • * Patients requiring SQ fat grafting for the amendment of any contour irregularity.
  • * Patients requiring other devices/drugs for skin contraction and/or cellulite treatment for the next 6 months (RF, US, Enzymes, etc.).
  • * Patients undergoing Face Lift procedures.
  • * Patients with any history of abnormal scarring and/or hypertrophic scars and or keloids.
  • * Patients with Caprini score ≥ 8.
  • * Patients with past medical history of connective tissue disease with active disease and/or recent relapse.
  • * Patients with past medical history thromboembolic disease or any other condition with an increased risk of coagulopathy (i.e., SLE, RA, APS).
  • * Patients using aspirin or any anticoagulant within 14 days and 5 days prior to surgery, respectively.
  • * Patients with a PMH of epilepsy or any epileptic syndrome and or vascular disease.
  • * Patients with any chronic disease non-compliant with treatment or non-adequately controlled.
  • * Positive pregnancy test or planning on getting pregnant in the next 6 months.
  • * Patients with fever or any other symptoms/signs of infection.
  • * Active smokers or chronic smokers with recent quit (≤ 4-8 weeks).
  • * Patients with prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) \>1.5 times baseline.

Ages Eligible for Study

18 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Total Definer Research Group,

Study Record Dates

2025-12-15